{
  "document_id": "91b83898",
  "zip_file": "kjxw0257.zip",
  "category": "Documents",
  "content_file": {
    "file_name": "kjxw0257.pdf",
    "file_path": "Documents/kjxw0257.zip/kjxw0257.pdf",
    "extracted_text": "=== Page 1 ===\nSource:  https://www.industrydocuments.ucsf.edu/docs/kjxw0257\n\n=== Page 1 Image 1 (OCR) ===\nPurduc Engagement Descriptions for Engagements Without SOWs\n\nEngagement\n\nApproximate\n\nApproximate\n\nDescription\n\nNumber\n\nStart Date\n\nEnd Date\n\nPUPOO]\n\n1/27/2004\n\n5/28/2004\n\nSupport cost reduction efforts and\n\nrevenue enhancement.\n\nPUPO02\n\n3/8/2004\n\n2/28/2005\n\nEnhance sales and marketing\n\nperformance, build capabilitics\n\nand support discussions on sales\n\npartnership.\n\nPUPOO3\n\n3/8/2004\n\n2/28/2005\n\nFurther information not available.\n\nPUPO04\n\n5/10/2004\n\n2/28/2005\n\nRedesign of R&D organization\n\nand key development processes.\n\nPUPOOS5\n\n6/14/2004\n\n6/27/2005\n\nDevelop a managed care strategy.\n\nPUPO06\n\n4/4/2005\n\n6/9/2005\n\nDesign and structure an alliance\n\ngovernance and management\n\nsystem and support negotiations of\n\nan alliance structure.\n\nPUPOO7\n\n9/21/2005\n\n10/31/2005\n\nCost reduction and performance\n\nscenario planning.\n\nPUPO32\n\n8/15/2011\n\n11/15/2011\n\nAssess the abuse diversion\n\nenvironment for opioids following\n\nthe shift to an abuse-resistant\n\nformulation (continuation of\n\nPUPO27, the SOW for which has\n\nbeen produced).\n\nPUPO34\n\n6/5/2013\n\n9/13/2013\n\nAssess brand performance of\n\nOxyContin (related to PUPO35.\n\nthe SOW for which has been\n\nproduced).\n\nPUPO38\n\n2/3/2014\n\n4/30/2014\n\nImplement prior recommendations\n\nto enhance brand performance of\n\nOxyContin (continuation of\n\nPUPO36, the SOW for which is\n\nbeing\n\nroduced).\n\nPUP047\n\n5/18/2015\n\n7/17/2015\n\nPerform benchmarking and\n\nwalkthroughs for four\n\nmanufacturing sites.\n\nPUPO52\n\n9/1/2015\n\n10/9/2015\n\nBuild strategic plan for ten priority\n\ninitiatives and develop metrics to\n\ntrack progress.\n\nMCK-MAAG-1392564\n\n=== Page 1 (Full Page OCR) ===\nPurdue Engagement Descriptions for Engagements Without SOWs\n\nEngagement\n\nApproximate\n\nApproximate\n\nDescription\n\nNumber\n\nStart Date\n\nEnd Date\n\nPUPOO!\n\n1/27/2004\n\n§/28/2004\n\nSupport cost reduction efforts and\n\nrevenue enhancement\n\nPUPOO2\n\n3/8/2004\n\n2/28/2005\n\nEnhance sales and marketing\n\nperformance, build capabilities\n\nand support discussions on sales\n\n_Partnership.\n\nPUPOO3\n\n3/8/2004\n\n2/28/2005\n\nFurther information not available.\n\nPUPO04\n\n5/10/2004\n\n2/28/2005\n\nRedesign of R&D organization\n\n—\n\na\n\ncy development proc\n\n-Y_CEVETO\n\nUPOOS\n\n14/2004\n\nlop a managed care s\n\nPUPOO06\n\n4/4/2005\n\n6/9/2005\n\nDesign and structure an alliance\n\ngovernance and management\n\nsystem and support negotiations of\n\nan alliance structure.\n\nPUPOO7\n\n9/21/2005\n\n10/31/2008\n\nCost reduction and performance\n\nsi\n\ncenario planning.\n\nPUPO32\n\n8/15/2011\n\n11/15/2011\n\nAssess the abuse diversion\n\nenvironment for opioids following\n\nthe shift to an abuse-resistant\n\nformulation (continuation of\n\nPUP027, the SOW for which has\n\nbeen produced)\n\nPUPO34\n\n6/5/2013\n\n9/13/2013\n\nAssess brand performance of\n\nOxyContin (related to PUPO35,\n\nthe SOW for which has been\n\n_produced).\n\nPUPO38\n\n2/3/2014\n\n4/30/2014\n\nImplement prior recommendations\n\nto enhance brand performance of\n\nOxyContin (continuation of\n\nPUPO036, the SOW for which is\n\nbeing produced).\n\nPUP047\n\n5/18/2015\n\n7/17/2015\n\nPerform benchmarking and\n\nwalkthroughs for four\n\nmanufacturing sites.\n\nPUPOS2\n\n9/1/2015\n\n10/9/2015\n\nBuild strategic plan for ten priority\n\ninitiatives and develop metrics to\n\ntrack progress\n\nSource: htt\n\n2S\n\nwww.industrydocument\n\ncsf.edu/docs/kjxw0257 MCK-MAAG-1392564",
    "extraction_method": "pymupdf+enhanced_ocr",
    "text_length": 3316,
    "errors": [],
    "success": true
  },
  "metadata_file": {
    "file_name": "kjxw0257-info.pdf",
    "file_path": "Documents/kjxw0257.zip/kjxw0257-info.pdf",
    "extracted_text": "=== Page 1 ===\nnull - kjxw0257 - Downloaded 31/03/2025 11:15:26 AM\nDocument Information\nTitle: Purdue Engagements Descriptions for Engagements Without SOWs.pdf\nURL: https://www.industrydocuments.ucsf.edu/docs/kjxw0257\nAuthor: Matos, Julie G.\nDocument Date: 2020 August 27\nType: Document\nGenre: Adobe Portable Document Format;Edoc\nPages: 1\nID: kjxw0257\nCollection: McKinsey Documents\nDrug: Oxycodone\nAvailability: public; no restrictions\nBates Number: MCK-MAAG-1392564\nDate Added UCSF: 2022 June 06\nCite This Document\nAuthor. Title. Date. Year. Collection. Source. https://www.industrydocuments.ucsf.edu/docs/[ID]\nMatos, Julie G.. Purdue Engagements Descriptions for Engagements Without SOWs.pdf. 2020 \nAugust 27. McKinsey Documents. Unknown. https://www.industrydocuments.ucsf.edu/docs/\nkjxw0257",
    "extraction_method": "pymupdf+enhanced_ocr",
    "text_length": 795,
    "errors": [],
    "success": true
  },
  "processed_at": "2025-06-12T12:22:36.415703"
}